We are now ready to partner in the therapeutics arena. We have just achieved our goal of creating the world’s best working genome editing platform. Founded 2012, we have since accumulated some of the most valuable IP in the field. TargetGene’s tightly knit teamis deeply passionate about bringing cures to patients.
Rishon LeZion, Israel
Founded in 2012
1-10 Employees
Working industry
Other
Type of company
Manufacturer
Locations
1 Headquarter
Number of products
3 Products
Specialised areas
Biotechnology, Genetics, Medical, Therapeutics
TargetGene Biotechnologies offers a wide range of products and services
Product
Technology – TARGETGENE
Go to product >
Product
Our Technology Video – TARGETGENE
Go to product >
Product
Our TGEE platform – TARGETGENE
Go to product >
An estimation about the ESG values based on digital data and signals. Important: The ESG scores are only based on information about the country, not the actual company itself
Country:
Israel
Overall risk estimation:
Low
The ESG Data of countries are based on public sources
Environment
B
Grade (A-E)
View details
Social
A
Grade (A-E)
View details
Governance
B
Grade (A-E)
View details
TargetGene Biotechnologies operates in 1 country around the world
Get an overview of the locations of TargetGene Biotechnologies
Location
Country
State
City
Headquarter
Israel
Center District
Rishon LeZion
Some frequent questions that have been asked about TargetGene Biotechnologies
Where is TargetGene Biotechnologies located?
The company headquarter of TargetGene Biotechnologies is located in Rishon LeZion, Center District, Israel. It's worth noting, that the company may have more locations
How many employees does TargetGene Biotechnologies approximately have?
As of the latest available information TargetGene Biotechnologies has around 1-10 employees worldwide.
When was TargetGene Biotechnologies founded?
TargetGene Biotechnologies was founded in 2012
In which industries does TargetGene Biotechnologies mainly work?
The company TargetGene Biotechnologies has it's main focus in the industries of Other
Check out some interesting alternative companies to TargetGene Biotechnologies
Scribe Therapeutics
United States
11-50 Employees
2017
Join our mission to engineer the next 20 years of gene editing breakthroughs - today. Pioneering novel viral and non-viral delivery technologies to truly enable in vivo genetic medicine. Built for exceptional specificity within the genome – enabling therapeutic precision and allele specific targeting.
Life Edit
Morrisville, United States
11-50 Employees
2017
We are scientific pioneers with unlimited potential to cure genetic disease. We are scientists and leaders on a shared mission to make innovative, curative therapies available to patients with devastating genetic diseases. We are guided by curiosity, rigor, and integrity. We are pioneers with unlimited potential to cure genetic disease. Our highly innovative, next-generation platform allows us to target any genomic sequence and develop life-changing therapies for the most challenging genetic disorders. They were developed from a proprietary collection of non-pathogenic organisms and offer gene editing tools with higher fidelity, novel functionality, reduced immune response risk, and easier delivery. Life Edit Therapeutics has joined ElevateBio’s portfolio of therapeutic, technology, and manufacturing companies and reimagined our identity. Our brand is an expression of our values, mission, and commitment to paving the way to faster, safer, more innovative gene editing therapeutics that treat diseases once thought to be incurable.
Alia Therapeutics
Italy
1-10 Employees
2018
We are developing next-generation gene editing medicines to cure rare genetic diseases at their roots by correcting inborn genetic errors directly in patients’ cells. Founded in 2018 based on the scientific discoveries of Anna Cereseto’s laboratory.
CureGenetics
Suzhou City, China
51-100 Employees
2016
Cure Genetics, is a clinical-stage biotechnology dedicated to developing first-in-class cell and gene therapies for solid tumors and genetic disorders through our innovative AIMS CAR-NKT and VELPTM AAV discovery platforms. We aim to provide effective treatment measures for patients worldwide with unmet medical needs and to become a benchmark in the global field of cell and gene therapies. Founded Cure Genetics in 2016, dedicated to developing innovative gene and cell therapies for genetic diseases and tumors. Ren is a seasoned expert in cell therapy, boasting over 20 years of experience developing and advancing cell therapy drug candidates from pre-clinical to commercial licensure across US, EU, and Japan. Ren has supported multiple IND submissions for cell therapy pipeline products to enable clinical trials and designed and led process & analytical validation programs in support of commercial registration filing. Shawn will guide the navigation of Cure Genetics' cell therapy development, leading the team to break new ground and accelerate the progress of cell therapy pipelines. We have built 4000m2 R&D, enzyme raw material manufacturing and IVD GMP manufacturing center in order to quickly promote the registration filings of our core products.
StrideBio
Durham, United States
51-100 Employees
2015
Our mission is to develop best-in-class gene therapies for people with life-threatening diseases. Our vision is to be the leader in the evolution of gene therapy and be known for superior drug development, high industry standards, extraordinary integrity and an innovative team that translates science into treatments that prolong and improve lives.
Tessera Therapeutics
Cambridge, United States
11-50 Employees
2018
Our mission is to cure disease by writing in the code of life. We are pioneering tissue-targeted non-viral delivery technology to make genomic alterations where they are needed. The first of its kind, Gene Writing is a versatile technology platform that can permanently make small and large alterations to the human genome.